Anti α6

Caki-1^res and Caki-1^par cells were detached from their culture flasks by Accutase and washed in blocking solution (PBS, 0.5% BSA). The cells were then incubated for 60 minutes at 4°C with phycoerythrin (PE)-conjugated monoclonal antibodies (mAbs) directed against the following integrin subtypes: anti-α1 (mouse IgG1, clone SR84), anti-α2 (mouse IgG2a, clone 12 F1-H6), anti-α3 (mouse IgG1, clone C3 II.1), anti-α4 (mouse IgG1, clone 9 F10), anti-α5 (mouse IgG1, clone IIA1), anti-α6 (rat IgG2a, clone GoH3), anti-β1 (mouse IgG1, clone MAR4), anti-β3 (mouse IgG1, clone VI-PL2), or anti-β4 (rat IgG2a; clone 439–9B; all: BD Biosciences). Tumor cell integrin expression was then measured using a FACScan (BD Biosciences; FL-2H (log) channel histogram analysis; 1 × 10⁴ cells per scan) and expressed as mean fluorescence units. A mouse IgG1-PE (MOPC-21) or IgG2a-PE (G155–178; all: BD Biosciences) was used as an isotype control.

Tumor cells were washed in blocking solution (PBS, 0.5% BSA) and then incubated for 60 min at 4 C with phycoerythrin (PE)-conjugated monoclonal antibodies directed against the following integrin subtypes: Anti-α1 (IgG1; clone SR84), anti-α2 (IgG2a; clone 12F1–H6), anti-α3 (IgG1; clone C3II.1), anti-α4 (IgG1; clone 9F10), anti-α5 (IgG1; clone IIA1), anti-α6 (IgG2a; clone GoH3), anti-β1 (IgG1; clone MAR4), anti-β3 (IgG1; clone VI-PL2) or anti-β4 (IgG2a; clone 439–9B; all: BD Pharmingen, Heidelberg, Germany). Integrin expression of tumor cells was then measured using a FACscan (BD Biosciences, Heidelberg; FL-2H (log) channel histogram analysis; 1×10⁴ cells/scan) and expressed as mean fluorescence units. A mouse IgG1-PE (MOPC-21) or IgG2a-PE (G155–178; all: BD Biosciences) was used as an isotype control.

Tumor cells were washed in blocking solution (PBS, 0.5% BSA) and then incubated for 60 min at 4 °C with phycoerythrin (PE)-conjugated monoclonal antibodies directed against the following integrin subtypes: anti-α1 (mouse IgG1; clone SR84; #559596), anti-α2 (mouse IgG2a; clone 12F1-H6; #555669), anti-α3 (mouse IgG1; clone C3II.1; #556025), anti-α4 (mouse IgG1; clone 9F10; #555503), anti-α5 (mouse IgG1; clone IIA1; #555617), anti-α6 (mouse IgG2a; clone GoH3; #555736), anti-β1 (mouse IgG1; clone MAR4; #555443), anti-β3 (mouse IgG1; clone VI-PL2; #555754) or anti-β4 (rat IgG2b; clone 439-9B; #555720) (all from BD Pharmingen, Heidelberg, Germany). Integrin expression of tumor cells was then measured using a FACScan (BD Biosciences; FL-2H (log) channel histogram analysis; 1 × 10⁴ cells/scan) and expressed as mean fluorescence units (MFU). Mouse IgG1-PE (MOPC-21; #555749), IgG2a-PE (G155-178; #555574), and rat IgG2b-PE (R35-38; #555848; all from BD Biosciences) were used as isotype controls.

Cancer cells were detached using accutase (PAA Laboratories GmbH, Pasching, Austria) and washed with blocking solution (PBS, 0.5% BSA). The cells were then incubated for 1 h at 4 °C with 20 µL ready-to-use phycoerythrin (PE) conjugated monoclonal antibody, directed against the following integrin subtypes: anti-α2 (IgG2a; clone 12F1-H6, 20 µL), anti- α3 (IgG1; clone C3II.1, 20 µL), anti- α5 (IgG1; clone IIA1, 20 µL), anti- α6 (IgG2a; clone GoH3, 20 µL), anti-β1 (IgG1; clone MAR4, 20 µL), anti- β 3 (IgG1; clone VI-PL2, 20 µL), or anti- β4 (IgG2a; clone 439-9B, 20 uL; all: BD Biosciences). 10 µL of anti-αV (IgG1; clone 13C2, Abcam, Cambridge, UK) was also used according to the manufacturer’s instructions. The integrin expression of tumor cells was then measured using a FACscan (BD Biosciences; FL2-H (log) channel histogram analysis; 1 × 10⁴ cells per scan) and expressed as mean fluorescence units. Mouse IgG1-PE (MOPC-21), mouse IgG2a-PE (G155-178) or rat IgG2b-PE (R35-38; all: BD Biosciences) was used as isotype control.